Overview
David Rosenbloom, as counsel to Amgen, said to the Second Circuit that a whistleblower’s allegations about Medicare reimbursement for the drug maker’s anemia biologic told the Centers for Medicare and Medicaid Services “nothing it didn’t already know.” The court agreed and dismissed the Fair Claims Act lawsuit.